Myogrel 75 mg, 300 mg

Indication :

Secondary prevention of atherothrombotic events
Clopidogrel is indicated in:
o Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic
stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
o Adult patients suffering from acute coronary syndrome:
-Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial
infarction), including patients undergoing a stent placement following percutaneous coronary
intervention, in combination with acetylsalicylic acid (ASA).
-ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients
eligible for thrombolytic therapy.
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not
suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is
indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events,
including stroke.

Composition :

Myogrel 75 mg film-coated tablets Each film-coated tablet contains 97.857 mg of Clopidogrel Bisulfate (Eq. to 75 mg Clopidogrel)